| Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| Author(s) : Furuhashi M , Sakuma I , Morimoto T , Higashiura Y , Sakai A , Matsumoto M , Sakuma M , Shimabukuro M , Nomiyama T , Arasaki O , Node K , Ueda S |
| Ref : Cardiovasc Diabetol , 19 :89 , 2020 |
| Abstract : |
| PubMedSearch : Furuhashi_2020_Cardiovasc.Diabetol_19_89 |
| PubMedID: 32539832 |
| Title : Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial - Ueda_2018_Cardiovasc.Drugs.Ther_32_73 |
| Author(s) : Ueda S , Shimabukuro M , Arasaki O , Node K , Nomiyama T , Morimoto T |
| Ref : Cardiovasc Drugs Ther , 32 :73 , 2018 |
| Abstract : |
| PubMedSearch : Ueda_2018_Cardiovasc.Drugs.Ther_32_73 |
| PubMedID: 29435776 |
| Title : Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice - Ervinna_2013_Endocrinology_154_1260 |
| Author(s) : Ervinna N , Mita T , Yasunari E , Azuma K , Tanaka R , Fujimura S , Sukmawati D , Nomiyama T , Kanazawa A , Kawamori R , Fujitani Y , Watada H |
| Ref : Endocrinology , 154 :1260 , 2013 |
| Abstract : |
| PubMedSearch : Ervinna_2013_Endocrinology_154_1260 |
| PubMedID: 23337530 |